Kamada Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Kamada şirketinin yıllık kazanç ve gelirinin sırasıyla 16.3% ve 8.2% oranında artması bekleniyor.

Anahtar bilgiler

16.3%

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi	48.5%
Gelir büyüme oranı	8.2%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	19 Aug 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality

Mar 14

Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%

Dec 30

Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year

Dec 22

Is Kamada (TLV:KMDA) Using Too Much Debt?

Jan 26

We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed

Dec 16

Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%

Mar 01

Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?

Feb 08

Is Weakness In Kamada Ltd. (TLV:KMDA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Jan 21

Kamada Ltd. (TLV:KMDA) Shares Could Be 42% Below Their Intrinsic Value Estimate

Jan 03

How Many Kamada Ltd. (TLV:KMDA) Shares Have Insiders Sold, In The Last Year?

Dec 15

Are Kamada's (TLV:KMDA) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 29

Kazanç ve Gelir Büyüme Tahminleri

TASE:KMDA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	193	21	28	33	3
12/31/2025	173	17	23	15	3
12/31/2024	161	14	18	24	3
6/30/2024	155	15	11	20	N/A
3/31/2024	150	12	1	8	N/A
12/31/2023	143	8	-2	4	N/A
9/30/2023	152	6	2	7	N/A
6/30/2023	146	3	6	11	N/A
3/31/2023	132	-2	16	20	N/A
12/31/2022	129	-2	25	29	N/A
9/30/2022	115	-10	13	17	N/A
6/30/2022	106	-12	5	9	N/A
3/31/2022	107	-7	-10	-5	N/A
12/31/2021	104	-2	-13	-9	N/A
9/30/2021	104	4	4	9	N/A
6/30/2021	116	12	4	9	N/A
3/31/2021	125	15	18	23	N/A
12/31/2020	133	17	14	19	N/A
9/30/2020	134	21	11	15	N/A
6/30/2020	132	20	20	23	N/A
3/31/2020	134	23	17	20	N/A
12/31/2019	127	22	25	28	N/A
9/30/2019	143	35	23	25	N/A
6/30/2019	125	26	18	20	N/A
3/31/2019	124	26	8	11	N/A
12/31/2018	114	22	8	11	N/A
9/30/2018	102	11	5	8	N/A
6/30/2018	110	13	2	5	N/A
3/31/2018	109	12	N/A	8	N/A
12/31/2017	103	7	N/A	4	N/A
9/30/2017	91	-1	N/A	2	N/A
6/30/2017	88	-2	N/A	2	N/A
3/31/2017	74	-8	N/A	-5	N/A
12/31/2016	77	-7	N/A	2	N/A
9/30/2016	79	-4	N/A	-6	N/A
6/30/2016	76	-8	N/A	-5	N/A
3/31/2016	76	-8	N/A	-5	N/A
12/31/2015	70	-11	N/A	-14	N/A
9/30/2015	69	-11	N/A	-8	N/A
6/30/2015	70	-9	N/A	-12	N/A
3/31/2015	67	-15	N/A	-10	N/A
12/31/2014	71	-13	N/A	-10	N/A
9/30/2014	71	-13	N/A	-7	N/A
6/30/2014	71	-10	N/A	-6	N/A
3/31/2014	71	-1	N/A	-6	N/A
12/31/2013	71	0	N/A	-4	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: KMDA 'nin tahmini kazanç büyümesi (yıllık 16.3% ) tasarruf oranının ( 2.5% ) üzerindedir.

Kazançlar ve Piyasa: KMDA şirketinin kazançlarının (yıllık 16.3% ) IL pazarından (yıllık 20.6% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: KMDA şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: KMDA şirketinin gelirinin (yıllık 8.2% ) IL pazarından (yıllık 2.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: KMDA şirketinin gelirinin (yıllık 8.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: KMDA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Kamada Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Kamada Ltd. Provides Earnings Guidance for the Year 2024

Kamada Ltd. Raises Earnings Guidance for the Year 2024

Kamada Ltd. Provides Revenue Guidance for the Year 2024

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2023

Kamada Ltd. Provides Revenue Guidance for the Fiscal Year 2022

Kamada Ltd. Provides Earnings Guidance for the Second Half of Year and Full Year 2022

Recent updates

Kamada Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Kamada Ltd., Annual General Meeting, Dec 11, 2024

Second quarter 2024 earnings released: EPS: US$0.08 (vs US$0.04 in 2Q 2023)

Kamada Ltd. Provides Earnings Guidance for the Year 2024

Kamada Ltd. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings released

Kamada Ltd. Raises Earnings Guidance for the Year 2024

Kamada Ltd. to Report Q1, 2024 Results on May 08, 2024

Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: US$0.17 (vs US$0.052 loss in FY 2022)

Kamada Ltd. Provides Revenue Guidance for the Year 2024

Kamada Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%

Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year

Investor sentiment improves as stock rises 19%

Third quarter 2023 earnings released: EPS: US$0.07 (vs US$0.011 in 3Q 2022)

Kamada Ltd., Annual General Meeting, Dec 28, 2023

Kamada Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Kamada Ltd. Announces Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

New minor risk - Shareholder dilution

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.09 loss in 2Q 2022)

Kamada Ltd. to Report Q2, 2023 Results on Aug 16, 2023

First quarter 2023 earnings released: US$0.04 loss per share (vs US$0.04 loss in 1Q 2022)

Kamada Ltd. announced that it expects to receive $59.85 million in funding from First Israel Mezzanine Investors Ltd.

Kamada Ltd. to Report Q1, 2023 Results on May 24, 2023

Kamada Ltd. Announces Receipt of Marketing Authorization for Glassia for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

Kamada Ltd. Announces U.S. FDA Approval of Its Application to Manufacture CYTOGAM At the Company’s Facility in Israel

Full year 2022 earnings released: US$0.05 loss per share (vs US$0.05 loss in FY 2021)

Is Kamada (TLV:KMDA) Using Too Much Debt?

Kamada Ltd. Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® At the Company’s Facility in Israel

Kamada Ltd. Appoints Uri Botzer as Members of Board of Directors

Kamada Announces Planned Transition of Chaime Orlev, Chief Financial Officer, Effective March 15, 2023

We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed

Third quarter 2022 earnings released: EPS: US$0.01 (vs US$0.02 loss in 3Q 2021)

Kamada Ltd. Provides Revenue Guidance for the Fiscal Year 2022

Kamada Ltd. to Report Q3, 2022 Results on Nov 22, 2022

High number of new directors

Kamada Ltd., Annual General Meeting, Dec 22, 2022

Kamada Ltd. Updates on Recent Progress Achieved in Ongoing Pivotal Phase 3 InnovAATe Clinical Trial

Second quarter 2022 earnings released: US$0.09 loss per share (vs US$0.02 profit in 2Q 2021)

Kamada Ltd. Provides Earnings Guidance for the Second Half of Year and Full Year 2022

Kamada Ltd. to Report Q2, 2022 Results on Aug 17, 2022

Kamada Ltd. Provides Earnings Guidance for the Full Year of 2022

First quarter 2022 earnings released: US$0.04 loss per share (vs US$0.06 profit in 1Q 2021)

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022

Kamada Ltd. to Report Q1, 2022 Results on May 17, 2022

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Kamada Ltd. to Report Q4, 2021 Results on Mar 15, 2022

Kamada Ltd. Acquires Portfolio of Four Plasma-Derived Hyperimmune Commercial Products from Saol Therapeutics

Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint

Kamada Ltd.(TASE:KMDA) dropped from TA-125 Index

Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.08 in 2Q 2020)

Kedrion Biopharma and Kamada Ltd. Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

First quarter 2021 earnings released: EPS US$0.06 (vs US$0.12 in 1Q 2020)

Kamada Ltd. (TASE:KMDA) completed the acquisition of Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc.

New 90-day low: ₪20.12

Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%

Full year 2020 earnings released: EPS US$0.39 (vs US$0.55 in FY 2019)

Revenue misses expectations

Investor sentiment improved over the past week

New 90-day high: ₪24.74

Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?

Kamada Ltd. to Report Q4, 2020 Results on Feb 10, 2021

Kamada Ltd. (TASE:KMDA) entered into an agreement to acquire Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc. for $1.6 million.

Is Weakness In Kamada Ltd. (TLV:KMDA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Kamada Ltd. Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel